Skip to main content
. 2016 Sep 1;116(4):659–668. doi: 10.1160/TH16-03-0179

Figure 1:

Figure 1:

Patient enrolment and study flow diagram. The diagram shows the flow and disposition of patients in the study. Following screening, 27 patients were enrolled in the study. All patients participated in PK evaluation of 50 IU/kg rIX-FP. A subset of patients (n=17) also participated in a PK evaluation of their previous FIX product (pdFIX or rFIX). All patients were assigned weekly prophylaxis with a dose of 35–50 IU/kg. All patients completed the study. FIX, factor IX; pdFIX, plasma-derived FIX; PK, pharmacokinetics; rFIX, recombinant FIX; rIX-FP, recombinant fusion protein linking coagulation factor IX with albumin.